Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-189 +/- Anti-PD-1 in Advanced Solid Tumors
NCT05370755Phase 1Not yet recruiting
- Sponsor
- InnoCare Pharma
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ICP-189 in solid tumor (advanced stage) (2 arms), sponsored by InnoCare Pharma. Primary endpoints: Incidence and severity of adverse events at 2 years, Dose-Limiting Toxicities at 2 years and 1 more. Planned start May 2022; status: not yet recruiting.
02
Drugs
ICP-189
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05370755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370755.